Abstract:RAS proteins are critical in cellular signal transduction, influencing cell proliferation,
differentiation, and survival. While extensively studied for their role in cancer, RAS gene mutations
also contribute significantly to cardiovascular diseases, such as hypertrophic cardiomyopathy,
pulmonary valve stenosis, and atrial septal defects. Despite their similar primary structures,
RAS proteins exhibit distinct functions in cardiac biology: H-RAS regulates cardiomyocyte size,
K-RAS governs proliferation, and N-RAS, less associated with cardiac defects, is understudied
in cardiac cells. Congenital RAS mutations, collectively known as RASopathies, include syndromes,
like Noonan syndrome and cardio-facio-cutaneous syndrome, which often lead to severe
cardiac complications, including heart failure. Genetic testing and imaging advances have
improved the diagnosis and management of these conditions. Recent research has shown promise
with MEK inhibitors and other targeted therapies, offering potential improvements in managing
RAS-related cardiac conditions. This review explores the role of the RAS subfamily in
heart disease, highlighting key concepts and potential therapeutic targets.
PubMed database was searched using keywords, such as RASopathies, RAS gene mutations, cardiac
hypertrophy, cardiovascular disease, RAS/MAPK pathway, congenital heart disease, and more. Relevant
literature up to June 2024 was examined and summarized, consisting of data from various clinical
trials, meta-analyses, retrospective/prospective cohort studies, and current guidelines.